Unmet Medical Needs

Th2-low asthma

There is no effective treatment to mitigate Th2-low asthma, for which there are 170,000 patients in the U.S.

Lung Transplants

There is a need to rehabilitate and improve lung function and preserve donor lungs ex-vivo to increase the supply of viable lungs and improve outcomes for transplantation for individuals with end stage lung disease

Pulmonary Fibrosis

Pulmonary Fibrosis is a progressive deadly disease that kills 40,000 people annually
50,000 new cases diagnosed per year, median survival is 3-5 years
Many patients go on to require a lung transplant, which has poor survival rates
There is a clear need for new therapies to treat Pulmonary Fibrosis

Solution: LGM2605 – novel small molecule


  • As an oral treatment for Th2-low asthma
  • To salvage donor lung organs that are currently not suitable for lung transplant
  • To improve donor lung storage conditions and extend the donor lung preservation period
  • As an oral treatment for Pulmonary Fibrosis
    • Control and in some cases reverse progression of the disease
    • Improve Pulmonary Fibrosis patient mobility/quality of life
    • Use alone or in combination with existing therapies


  • Preventing/treating Periodontitis
  • Supportive care to prevent lung damage during radiation treatment of thoracic cancers
  • Mitigation agent to treat radiation lung damage from nuclear accident or attack
    • Contract awarded by NIAID to support development activities required for FDA approval under the Animal Rule. If the development program is successful, LGM2605 will be a candidate for procurement for the U.S. Strategic National Stockpile.